The company trades and distributes a variety of pharmaceutical raw materials, active pharmaceutical ingredients (APIs), and industrial chemicals to manufacturers in Gujarat.
The company lacks a durable competitive advantage as it operates as a pure trading intermediary in a fragmented market with low barriers to entry. Financial metrics contradict any moat claim, with ROCE at a mediocre 7% and a massive disconnect between revenue growth and collapsing earnings per share.
Management has deployed capital into significant unsecured loans and advances to related parties rather than productive business assets. These advances, totaling over 16 crore rupees, lack clear repayment terms or interest income, suggesting value extraction rather than value creation.
The investment collapsed as the massive disconnect between soaring revenue and cratering earnings per share finally resolved in a total wipeout. The tax authorities likely moved from assessment to enforcement, freezing assets over the 21.98 crore rupee GST dispute and the 15 crore rupee tax demands. Meanwhile, the interest-free loans to related parties were never repaid, effectively siphoning the remaining equity out of the business. The lack of internal controls and audit trails allowed these irregularities to compound until the company was delisted or declared a going concern failure, leaving minority shareholders with nothing but a shell.
RichFakir rates Patron Exim Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Patron Exim Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →